drugset
drugset / Trial / NCT03123185

Safety and Pharmacokinetics of Single Rising Doses of BI 705564 and Food Effect on BI 705564 in Healthy Male Subjects

NCT03123185 ↗

Phase 1 Completed 91 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

Investigation of safety, tolerability, pharmacokinetics and pharmacodynamics of single rising doses of BI 705564 and of the food effect on BI 705564 in healthy male subjects

Timeline

Start
2017-04-27
Primary completion
2018-02-19
Completion
2018-02-19

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 705564 Unknown 1 mg Oral
Subject BI 705564 Unknown 3 mg Oral
Subject BI 705564 Unknown 10 mg Oral
Subject BI 705564 Unknown 20 mg Oral
Subject BI 705564 Unknown 40 mg Oral
Subject BI 705564 Unknown 80 mg Oral
Subject BI 705564 Unknown 160 mg Oral

Indications

No indication recorded.